Effects of carvedilol on cardiomyocyte apoptosis and gene expressionin vivo after ischemia-reperfusion in rats

Abstract

The effects of carvedilol on cardiomyocyte apoptosis and expression of bcl-2, bax genes following ischemia (0.5 h) and reperfusion (48 h)in vivo and the possible biological mechanism of carvedilol inhibiting cardiomyocyte apoptosis were studied. The left anterior descending artery in Wistar rats were ligated to establish ischemia-reperfusion (I/R) models. The model animals were divided into two groups: I/R group, the model rats not subject to other treatments except ischemia-reperfusion (n=8): carvedilol-treated group (n=8), I/R model rats treated with carvedilol. Eight rats in the sham-operated group were subjected to only experimental open operation. The number of apoptotic cardiomyocyte was determined by TUNEL staining. Immunohistochemistry andin situ hybridization histochemistry (ISHH) were used to detect the expression of bcl-2 and bax genes. Image processing system was used to quantitatively dispose the positive metric substances of both immunohistochemistry and ISHH through the average optical density (OD) value. The results showed that the number of the apoptotic cells were 36.18±9 (I/R group), 0–1 (sham-operated group) and 9.5±3 (carvedilol-treated group) in each visual field respectively with the difference being very significant among the groups (P<0.001). The OD values of bcl-2 protein in sham-operated group, I/R group and carvedilol-treated group were 0.14±0.01, 0.08±0.02 and 0.15±0.03, respectively. The OD values of bcl-2 mRNA in sham-operated group, I/R group and carvedilol-treated group were 0.08±0.01, 0.06±0.01 and 0.09±0.01, respectively. There was no significant difference between carvedilol-treated group and I/R group (P>0.05). The OD values of bax protein in I/R group, sham-operated and carvedilol-treated-treated group were 0.13±0.02, 0.07±0.01, 0.06±0.01, respectively. There was very significant difference between carvedilol-treated group and I/R group (P<0.01). Bcl-2/bax ratio was 1.07±0.14 (I/R group), 1.28±0.16 (sham-operated group), 2.5±0.26 (carvedilol-treated group) respectively with the difference being very significant between carvedilol-treated group and I/R group (P<0.05). It was indicated that carvedilol could inhibit cardiomyocyte apoptosis following ischemia and reperfusion, which was related to the increased bcl-2/bax ratio due to inhibition of bax gene expression.

Keywords

carvedilol / ischemia-reperfusion / apoptosis / gene expression

References

[1] PiperH M, Garcia-DoradoD, OvizeM. A fresh look at reperfusion injury. Cardiovasc Res, 1998, 38(2): 291-291

[2] MaxwellS R, LipG Y. Reperfusion injury: a review of the pathophysiology, clinical manifestations and therapeutic options. Intern J Cardiol, 1997, 58(2): 95-95

[3] FlissH, GaottingerD. Apoptosis in ischemic and reperfusion rat myocardium. Circ Res, 1996, 79(5): 949-949

[4] PalojokiE, SarasteA, ErikssonA, et al. . Cardiomyocyte apoptosis and ventricular remodeling after myocardial infarction in rats. Am J Physiol Heart Circ Physiol, 2001, 280H2726-H2726

[5] HolleymanC R, LarsonD F. Apoptosis in the ischemic reperfused myocardium. Perfusion, 2001, 16(6): 491-491

[6] MaulikN, SasakiH, GalangN. Differential regulation of apoptosis by ischemia-reperfusion and ischemic adaptation. Ann N Y Acad Sci, 1999, 874401-401

[7] FreudeB, MastersT N, RobicsekF, et al. . Apoptosis is initiated by myocardial ischemia and executed during reperfusion. J Mol Cell Cardiol, 2000, 32(2): 97-97

[8] FeuersteinG Z, BrilA, RuffoloR R. Protective effects of carvedilol in the myocardium. Am J Cardiol, 1997, 80(11A): 41L-41L

[9] GaoF, ChenJ, LopezB L, et al. . Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model. Eur J Pharmacol, 2000, 406(1): 109-109

[10] XieZ, Koyama, SuzukiJ, et al. . Coronary reperfusion following ischemia: different expression of bcl-2 and bax proteins and cardiomyocyte apoptosis. Jpn Heart J, 2001, 42(6): 759-759

[11] BookW M. Carvedilol: a nonselective beta blocking agent with antioxidant properties. Congest Heart Fail, 2002, 8(3): 173-173

[12] YueT L, MaX L, WangX W, et al. . Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia-reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circ Res, 1998, 82166-166

[13] HabonT, SzabadosE, KesmarkyG, et al. . The effect of carvedilol on enhanced ADP-ribosylation and red blood cell membrane damage caused by free radicals. Cardiovasc Res, 2001, 52(1): 153-153

[14] CookS A, SugdenP H, ClerkA. Regulation of Bcl-2 family protein during development and in response to oxidative stress in cardiac myocyte: association with changes in mitochondria membrane potential. Circ Res, 1999, 85(10): 940-940

[15] LiuL, AzharG, GaoW, et al. . Bcl-2 and Bax expression in adult rat hearts after coronary occlusion: age-associated differences. Am J Physiol, 1998, 275R315-R315